no small cell lung cancer
Conditions
Interventions
Test group:Cryoablation combined with Immunochemotherapy
Control group:Immunochemotherapy
Sponsors
Yueyang Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age >=18 years old; 2. Pathological diagnosis of non-small cell lung cancer (adenocarcinoma or squamous cell carcinoma) confirmed by biopsy, EGFR and ALK negative, KRASG12D/KEAT1/STK11 mutation patient; 3. Staging (TNM 8th edition, TxNxM1 stage IV); 4. ECOG physical condition score: 0-1 points, able to tolerate puncture; 5. No anti-tumor treatment has been performed; 6. The main organs function well, without serious hypertension, diabetes and heart disease; 7. Sign the informed consent form; 8. Good compliance, family members agree to cooperate in receiving survival follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with abnormal coagulation function and bleeding tendency (must meet the requirement of INR being within the normal range without using anticoagulants within 14 days before randomization); Patients treated with anticoagulants or vitamin K antagonists such as warfarin, heparin, or their analogues; Under the premise that the international normalized ratio (INR) of prothrombin time is <=1.5, it is allowed to use low-dose warfarin (1mg orally, once daily) or low-dose aspirin (daily dose not exceeding 100 mg) for preventive purposes; 2. Individuals with a history of abuse of psychotropic drugs who are unable to quit or have mental disorders; 3. Screening for arterial/venous thrombosis events that have occurred within the previous 6 months, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis (excluding those caused by venous catheterization during previous chemotherapy and judged to have recovered by researchers), and pulmonary embolism; 4. According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect the completion of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression-free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival (OS);objective response rate (ORR);disease control rate (DCR); | — |
Countries
China
Contacts
Public ContactLuo Pan
Yueyang Central Hospital
Outcome results
None listed